Literature DB >> 34904023

Updates in Psoriasis Management: Based on selected presentations from Maui Derm 2021 on January 25-29 in Grand Wailea, Maui, Hawaii.

Jo Ann LeQuang1.   

Abstract

Entities:  

Year:  2021        PMID： 34904023      PMCID： PMC8570349     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN： 1941-2789


× No keyword cloud information.
  68 in total

1.  Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.

Authors:  Kenneth B Gordon; Peter Foley; James G Krueger; Andreas Pinter; Kristian Reich; Ronald Vender; Veerle Vanvoorden; Cynthia Madden; Katy White; Christopher Cioffi; Andrew Blauvelt
Journal:  Lancet       Date:  2021-02-06       Impact factor: 79.321

2.  Does therapy with biological drugs influence COVID-19 infection? Observational monocentric prevalence study on the clinical and epidemiological data of psoriatic patients treated with biological drugs or with topical drugs alone.

Authors:  Valeria Brazzelli; Eugenio Isoletta; Oren Barak; Stefania Barruscotti; Camilla Vassallo; Chiara Giorgini; Andrea Michelerio; Carlo Francesco Tomasini; Valeria Musella; Catherine Klersy
Journal:  Dermatol Ther       Date:  2020-11-10       Impact factor: 2.851

Review 3.  Psoriatic arthritis: epidemiology, clinical features, course, and outcome.

Authors:  D D Gladman; C Antoni; P Mease; D O Clegg; P Nash
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

4.  Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study.

Authors:  Elizabeth G Araujo; Matthias Englbrecht; Sabrina Hoepken; Stephanie Finzel; Eleni Kampylafka; Arnd Kleyer; Sarah Bayat; Verena Schoenau; Axel Hueber; Juergen Rech; Georg Schett
Journal:  Semin Arthritis Rheum       Date:  2018-06-13       Impact factor: 5.532

Review 5.  Drug survival of biologic treatments in psoriasis: a systematic review.

Authors:  Daniel J No; Megan S Inkeles; Mina Amin; Jashin J Wu
Journal:  J Dermatolog Treat       Date:  2017-11-10       Impact factor: 3.359

Review 6.  Psoriatic Arthritis: Newer and Older Therapies.

Authors:  Robert Chao; Arthur Kavanaugh
Journal:  Curr Rheumatol Rep       Date:  2019-12-21       Impact factor: 4.592

Review 7.  Bedside to bench: defining the immunopathogenesis of psoriatic arthritis.

Authors:  Arlene Bravo; Arthur Kavanaugh
Journal:  Nat Rev Rheumatol       Date:  2019-09-04       Impact factor: 20.543

Review 8.  Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.

Authors:  W Joost Wiersinga; Andrew Rhodes; Allen C Cheng; Sharon J Peacock; Hallie C Prescott
Journal:  JAMA       Date:  2020-08-25       Impact factor: 56.272

9.  Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial.

Authors:  C Bodemer; A Kaszuba; K Kingo; A Tsianakas; A Morita; E Rivas; P Papanastasiou; D Keefe; M Patekar; P Charef; L Zhang; S Cafoncelli; C Papavassilis
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-01-19       Impact factor: 6.166

10.  Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).

Authors:  Peter Nash; Kamal Ohson; Jessica Walsh; Nikolay Delev; Dianne Nguyen; Lichen Teng; Juan J Gómez-Reino; Jacob A Aelion
Journal:  Ann Rheum Dis       Date:  2018-01-17       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.